The Consolidated Appropriations Act of 2026 (H.R. 7148), signed into law in early 2026, requires pharmacy benefit managers to remit 100% of manufacturer rebates, fees, alternative discounts, and other remuneration to ERISA plan sponsors on a quarterly basis. PBMs must pass those funds through no later than 90 days after each quarter-end, with upstream aggregators and group purchasing organizations facing a 45-day deadline. The mandate applies to contracts entered into or renewed on or after August 3, 2028, meaning calendar-year plans first feel the effect on January 1, 2029.
Who It Affects
Self-insured employer health plans that route pharmacy benefits through a PBM, which is nearly all of them. The law targets the retained-rebate and spread-pricing economics that have defined PBM compensation for decades. Mid-to-large self-insured employers, Taft-Hartley funds, and public-entity health plans whose PBM contracts include retained rebates or opaque spread arrangements face the most immediate contract renegotiation pressure. Plan sponsors entering the 2027 renewal cycle need to begin restructuring PBM agreements now to avoid hitting the compliance date with a non-conforming contract.
The Reserve Mechanism
The law changes the expected claim ratio for the pharmacy benefit line in two ways.
First, gross pharmacy claims will appear higher once PBMs shift from retained rebates to elevated per-member-per-month administrative fees. Plans that historically booked health plan IBNR on a net-of-rebate basis will see the pharmacy component of their incurred claims rise, even if total plan cost stays flat or declines. The Bornhuetter-Ferguson expected claim ratio that anchors recent-year pharmacy projections needs recalibration to reflect the new gross-versus-net split.
Second, the shift from annual rebate reconciliation to quarterly pass-through changes pharmacy cost development timing. Under the old model, rebate credits often arrived 12 to 18 months after the claim, creating a long development tail on the pharmacy line. Quarterly remittance compresses that tail. Aggregate stop-loss attachment points calibrated to historical pharmacy development patterns, which assumed a slow rebate offset, need recalibration. If the attachment was set using net development factors from the annual-reconciliation era, the plan may be over-attached for the new quarterly cadence.
Enforcement and Fiduciary Exposure
The penalties are steep. PBMs face $10,000 per day for failing to provide required information and $100,000 for each piece of knowingly false information. Non-compliant PBM contracts become prohibited transactions under ERISA, which means plan fiduciaries who fail to renegotiate their contracts before the compliance date take on personal fiduciary liability. The law does provide fiduciary relief when a PBM fails to remit required rebates, so long as the plan sponsor has satisfied certain diligence requirements, but that relief does not extend to sponsors who never updated their contracts. The companion DOL PBM fee disclosure rule, with final regulations expected by August 2027, adds a parallel layer of transparency obligations.
Plan sponsors also gain annual audit rights over PBM rebate contracts with manufacturers. The plan, not the PBM, selects the auditor, closing a longstanding conflict-of-interest gap.
What This Means for Your Next Review
Before your next reserve study or stop-loss renewal, ask your actuary to decompose the pharmacy expected claim ratio into gross claims and rebate offsets separately. If the current projection embeds a net-of-rebate cost assumption, it will understate gross pharmacy incurred once the pass-through takes effect and overstate the development tail. Model the quarterly rebate cadence against your aggregate stop-loss attachment to determine whether the attachment point needs adjustment for the compressed development pattern. For plans on a calendar-year cycle, the January 2029 effective date puts the 2027 renewal as the first contract that must be structured for compliance.
Sources
- Morgan Lewis: CAA 2026, The New Landscape of PBM Fiduciary Oversight
- Mintz: Congress Passes Landmark PBM Reform in 2026 Spending Bill
- Epstein Becker Green: 2026 PBM Reform, What Employers Need to Know
- WTW: PBM Disclosure and Rebate Pass-Through Provisions Enacted
- Groom Law Group: High-Level Comparison of DOL PBM Fee Disclosure Rule and CAA 2026